Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the
breast. The lump or mass is usually painless, hard & irregular but
it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple
discharge, nipple retraction and presence of breast skin changes (eg
peau d' orange, nipple excoriation, scaling, inflammation, skin
tethering, ulceration, abscess).
Adjuvant olaparib for 1 year following local treatment and adjuvant/neoadjuvant chemotherapy improved disease-free survival (DFS) in patients with HER2-negative early breast cancer (EBC) with BRCA1 or BRCA2 pathogenic/likely pathogenic variants and high recurrence risk, according to interim results of the multinational, phase III OlympiA study.
Young women with breast cancer who are receiving treatment with modern chemotherapy regimens are likely to develop short episodes of treatment-related amenorrhea, but the vast majority of them will maintain or regain menstrual function, a study has found.
The cardioprotective drugs metoprolol and candesartan had little benefit on cardiovascular (CV) outcomes when given alongside adjuvant anthracycline treatment in women with early breast cancer and low CV risk, long-term results of the PRADA* trial showed.
Skipping even one scheduled mammography screening prior to a breast cancer diagnosis could increase a woman’s risk of breast cancer mortality, according to a prospective, observational study from Sweden.
Ipatasertib plus paclitaxel in the first-line setting does not confer a progression-free survival (PFS) benefit to patients with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), according to a study presented at SABCS 2020.
The addition of pembrolizumab to chemotherapy led to better progression-free survival (PFS) compared with chemotherapy only in Asian patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), according to a subgroup analysis of the KEYNOTE-355 study presented at ESMO Asia 2020.
The addition of chemotherapy to endocrine therapy improved invasive disease-free survival (IDFS) in premenopausal women with lymph node-positive early stage hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer with recurrence score ≤25, according to early results of the phase III SWOG S1007 RxPonder* trial presented at SABCS 2020. However, the benefits did not appear to extend to postmenopausal women.
Women who received statins were less likely than those who did not to have ED* visits or hospitalizations for heart failure (HHF) following chemotherapy with anthracyclines for early breast cancer (EBC) — suggesting that statins may protect the heart against damage induced by chemotherapy, at least among older women.